Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

VEGF-VEGF receptor complexes as markers of tumor vascular endothelium.

Brekken RA, Thorpe PE.

J Control Release. 2001 Jul 6;74(1-3):173-81. Review.

PMID:
11489493
2.

Vascular endothelial growth factor as a marker of tumor endothelium.

Brekken RA, Huang X, King SW, Thorpe PE.

Cancer Res. 1998 May 1;58(9):1952-9.

3.

Vascular endothelial growth factor and vascular targeting of solid tumors.

Brekken RA, Thorpe PE.

Anticancer Res. 2001 Nov-Dec;21(6B):4221-9. Review.

PMID:
11908675
4.

Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.

Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE.

Cancer Res. 2000 Sep 15;60(18):5117-24.

5.

A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex.

Cooke SP, Boxer GM, Lawrence L, Pedley RB, Spencer DI, Begent RH, Chester KA.

Cancer Res. 2001 May 1;61(9):3653-9.

6.
7.

Involvement of VEGF and its receptors in ascites tumor formation.

Shibuya M, Luo JC, Toyoda M, Yamaguchi S.

Cancer Chemother Pharmacol. 1999;43 Suppl:S72-7.

PMID:
10357563
9.

Expression of VEGF-C and activation of its receptors VEGFR-2 and VEGFR-3 in trophoblast.

Dunk C, Ahmed A.

Histol Histopathol. 2001 Apr;16(2):359-75.

PMID:
11332691
10.

Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2.

Vajkoczy P, Farhadi M, Gaumann A, Heidenreich R, Erber R, Wunder A, Tonn JC, Menger MD, Breier G.

J Clin Invest. 2002 Mar;109(6):777-85.

11.

Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803.

Tian X, Song S, Wu J, Meng L, Dong Z, Shou C.

Biochem Biophys Res Commun. 2001 Aug 24;286(3):505-12.

PMID:
11511087
12.

Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium.

Paavonen K, Mandelin J, Partanen T, Jussila L, Li TF, Ristimaki A, Alitalo K, Konttinen YT.

J Rheumatol. 2002 Jan;29(1):39-45.

PMID:
11824969
13.

Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.

He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K.

J Natl Cancer Inst. 2002 Jun 5;94(11):819-25.

PMID:
12048269
14.

Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.

Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, Zhu Z, Witte L, Pepper MS.

J Pharmacol Exp Ther. 2001 Dec;299(3):1073-85.

16.

Lymphatic versus blood vascular endothelial growth factors and receptors in humans.

Partanen TA, Paavonen K.

Microsc Res Tech. 2001 Oct 15;55(2):108-21. Review.

PMID:
11596156
17.
19.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
20.

Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma.

Tsuchiya N, Sato K, Akao T, Kakinuma H, Sasaki R, Shimoda N, Satoh S, Habuchi T, Ogawa O, Kato T.

Tohoku J Exp Med. 2001 Oct;195(2):101-13.

Supplemental Content

Support Center